Brazil: Brazil Focus - Growth For The Biotech Sector

The Brazilian government is investing in the development of biopharmaceuticals through partnerships with innovative multinationals, local pharma companies and public research and development institutions, as Gabriela Salerno and Rana Gosain of Daniel Advogados report.

In 2001, the worldwide revenue of the pharmaceutical market was around $390 billion. Ten years later, this number increased to almost $1 trillion, with biopharmaceuticals accounting for approximately 15.7%. Forecasts show that this percentage is expected to exceed 20% by 2016. The key regions for the global biologics market are the US, Europe, Japan and Brazil, Russia, India and China, which together accounted for 83% of this market in 2014.

Based on these statistics, the research, development and innovation process of the pharma industry has been gradually changing due to the so-called modern biotechnology revolution, which represents a whole new world of possibilities for the treatment of autoimmune diseases, cancer and others.

However, several important differences between synthetic drugs and biopharmaceuticals must be taken into consideration. The former are usually small stable molecules which can be easily manipulated and obtained by a controlled process. On the other hand, biological drugs are quite complex and unstable molecules which can have their structures completely changed when subjected to minor variations.

Because of their complexity, identical copies of biopharmaceuticals are extremely difficult to produce and the processes for producing them play a critical role in maintaining their safety and efficacy. Large-scale biotech manufacturing facilities are at least five times more expensive to build compared with synthetic molecule facilities and are also more costly to run.

Therefore, biological drugs are often included in the expression 'the process is the product', indicating the significance of the manufacturing process to guarantee quality. Another parameter that is pivotal for biologics is immunogenicity, which is the ability of a substance to trigger an immune response. Since these substances are generally macromolecules, they are usually immunogenic and therefore they can provoke an immune response which can lead to serious consequences if not properly controlled, such as an immune tolerance breakdown—whereby the body cannot tolerate its own proteins.

In Brazil, the sixth largest pharma market in the world, retail sales jumped from R$28.7 billion ($8.3 billion) in 2010 to R$41.8 billion in 2014, representing an increase of 45.6% over that period. However, in the past few years, the market has undergone some changes. Innovative drugs, which accounted for 44% of sales in value terms in 2010, declined to 39% in 2014, while generics and follow-on biologics (also known as biosimilars) have gained market share, climbing from 55% in 2010 to 61% in 2014.

Although generic drugs are still of great importance to the Brazilian market, recent studies show the need for innovation in the pharma industry. Due to the exponential growth of biotech in the world, the production of biopharmaceuticals seems to have great potential to drive the Brazilian pharma industry.

One main reason for traditional pharma companies to invest in biotech processes for producing new drugs is the expiration of patents covering their blockbuster synthetic drugs in the past few years (the 'patent cliff'). Since Brazil is among the five most important markets for the majority of these companies, it is essential to carefully analyse the current patent scenario in this country.

Cause for optimism

Despite the Brazilian Patent and Trademark Office (INPI) having taken steps to increase the number of patent examiners, the backlog situation has not improved for the simple reason that during the last decade there has been a constant increase in patent filings in Brazil. However, some relevant developments are contributing to the creation a more optimistic scenario, such as the letter of intentions signed by the Brazilian and US governments whereby the INPI would adopt a Patent Prosecution Highway pilot programme to streamline the examination of patent applications, thereby reducing the huge backlog.

Although the pilot programme would apply only to the oil and gas industry, it would be a big step towards efficiency and it could certainly be extended to all technological fields. Also, the INPI published new examination guidelines for patent applications in the biotech field early this year, addressing issues that were not cited in the previous guidelines of 2002 and providing a more uniform and predictable analysis of these applications.

One important player in the examination of patent applications in the biotech/pharma fields in Brazil is the National Health Surveillance Agency (ANVISA), which introduced a significant change in patent prosecution with the publication of Resolution No. 21/2013. The resolution clearly states that besides analysing public health issues, ANVISA has the right to carry out a substantive examination before the INPI if the application refers to any of the active compounds that are said to be of interest to the Brazilian healthcare system.

Some biologicals are included in this list of compounds, such as monoclonal antibodies, enzymes, hormones, proteins, vaccines and haemoderivatives. In theory, if prior approval of an application is denied by ANVISA, it will be sent back to the INPI, which can shelve the application. So far, no patent application for which prior approval has been denied has been shelved by the INPI.

It is also possible to challenge ANVISA's intervention before the courts by alleging a lack of legal standing to perform a substantive examination. As a result, some courts have issued preliminary injunctions ordering ANVISA to grant prior approval of patent applications on the grounds that ANVISA did not have the competence to conduct a patentability examination.

On the other hand, an unexpected decision from the federal court in Rio de Janeiro in June denied a preliminary injunction and ruled that ANVISA is competent to examine pharma patent applications in terms of patentability requirements. In all likelihood this decision will be used by ANVISA to assert its legitimacy to examine pharma patent applications and Brazilian attorneys will have to be creative to overrule this decision.

In an attempt to keep up with the new biotech wave, the Brazilian government is investing in the development of biopharmaceuticals through partnerships with innovative multinationals, local pharma companies and public research and development institutions. The so-called product development partnerships (PDPs) are guided by the Brazilian Ministry of Health's Ordinance No. 2,531 of November, 2014, which establishes the mandatory requirements for submitting a PDP project.

One of the main objectives of a PDP is to transfer the technology involved in the manufacture of biological products to a Brazilian public R&D institution in order to improve local production and reduce government dependence on imported products.

The rules for approving biosimilars in Brazil are very similar to those adopted by countries considered as leaders in the field. Moreover, in order to be harmonised with international standards, ANVISA is currently issuing guidelines for specific product classes such as heparins and alphainterferon.

It is certain that the Brazilian federal government is keen on improving the country's drug development and medical research capacity so as to stimulate domestic industrial growth. It is therefore no surprise that the government is the primary sponsor of biotech sector growth. In addition, it intends to allocate more resources to spur innovation in local companies producing biological products, particularly for drugs treating cancer and rheumatoid arthritis.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.